DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Trial Details

NCT ID
NCT04920617
Phase
PHASE2
Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • DPX-Survivac
  • Pembrolizumab
  • CPA
Locations (sample)
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Boca Raton, Florida, United States|26.35869,-80.0831
  • Hollywood, Florida, United States|26.0112,-80.14949
  • Plantation, Florida, United States|26.13421,-80.23184
  • St. Petersburg, Florida, United States|27.77086,-82.67927

Key Eligibility Criteria

  • Adults ≥ 18 years of age who are willing and able to provide written informed consent
  • Have an ECOG performance status of ≤ 1. Subjects with an ECOG performance status of 2 may be enrolled with Medical Monitor approval.
  • Pathologically confirmed diagnosis of DLBCL, as defined by the 2016 World Health Organization classification including DLBCL NOS high-grade B-cell …
  • Subjects must have progressive disease following at least two (2) lines of prior systemic therapy for DLBCL; prior treatment must have included an …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →